Ikena Oncology Inc. recently executed a reverse stock split at a ratio of 1-for-12, as approved by its shareholders. Following this adjustment, Ikena merged with Inmagene Biopharmaceuticals to form ImageneBio, Inc. The newly combined company will begin trading on Nasdaq under the ticker symbol "IMA" starting July 28, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ikena Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-165170), on July 25, 2025, and is solely responsible for the information contained therein.